

BIOLIDICS LIMITED
(Company Registration No.: 200913076M)
(Incorporated in the Republic of Singapore)

**PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE (THE “RIGHTS ISSUE”) –
RECEIPT OF LISTING AND QUOTATION NOTICE FROM THE SGX-ST**

1. INTRODUCTION

- 1.1 The board of directors (the “**Board**”) of Biolidics Limited (the “**Company**”) refers to the Company’s announcement dated 29 September 2022 (the “**Previous Announcement**”) in relation to the Rights Issue.
- 1.2 Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Previous Announcement.

2. RECEIPT OF LISTING AND QUOTATION NOTICE

- 2.1 The Board is pleased to announce that the Company has on 25 October 2022, received the listing and quotation notice (the “**LQN**”) from the SGX-ST for the dealing in, listing of and quotation for, up to 265,721,200 Rights Shares on the Catalist board of the SGX-ST. The LQN from the SGX-ST is subject to compliance with the SGX-ST’s listing requirements.
- 2.2 The LQN is not to be taken as an indication of the merits of the Rights Issue, the Rights Shares, the Company and/or its subsidiaries.

3. CAUTIONARY STATEMENT

Shareholders and potential investors are advised to exercise caution when dealing or trading in the Shares. As at the date of this announcement, there is no certainty or assurance that the Rights Issue will be completed or that no changes will be made to the terms thereof. The Company will make the necessary announcements when there are further developments. Shareholders and potential investors are advised to read this announcement and any further announcements by the Company carefully. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers if they have any doubt about the actions they should take.

By Order of the Board

Song Tang Yih
Executive Director and Chief Executive Officer
26 October 2022

This announcement has been prepared by the Company and has been reviewed by the Sponsor for compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Lim Hoon Khat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.